Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of 3-Month vs 1-Month Dapivirine Vaginal Ring
NCT05416021Phase 1Completed
- Sponsor
- International Partnership for Microbicides
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by International Partnership for Microbicides. Primary endpoint: Relative Bioavailability of Dapivirine in Plasma at 90 days. Started Aug 2022; status: completed.
02
Drugs
dapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05416021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416021.